Krystle Lang Kuhs
Last active: 3/20/2020

HPV16 E6 seropositivity among cancer-free men with oral, anal or genital HPV16 infection.

Beachler DC, Waterboer T, Pierce Campbell ChM, Ingles DJ, Kuhs KA, Nyitray AG, Hildesheim A, Pawlita M, Kreimer AR, Giuliano AR
Papillomavirus Res. 2016 2: 141-144

PMID: 28239675 · PMCID: PMC5322843 · DOI:10.1016/j.pvr.2016.07.003

Antibodies against the Human papillomavirus 16 (HPV16) E6 oncoprotein appear years prior to clinical diagnosis of anal and oropharyngeal cancer, but whether they develop around the time of HPV infection is unclear. Serum samples from 173 cancer-free men from the Human Papillomavirus Infection in Men (HIM) Study were tested for HPV antibodies and DNA. HPV16 E6 seropositivity was low among men with oral HPV16-infection (1/28; 3.6%, 95%CI=0.0%-18.4%), anal HPV16-infection (1/61; 1.6%, 95%CI=0.0%-8.8%), and 24-month persistent genital HPV16-infection (1/84; 1.2%, 0.0-6.5%). This suggests E6 seroconversion may not occur around the time of oral, anal, or genital HPV16 acquisition.

MeSH Terms (0)

Connections (2)

This publication is referenced by other Labnodes entities: